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Members of the PKC (protein kinase C) superfamily play key
regulatory roles in glucose transport. How the different PKC
isotypes are involved in the regulation of glucose transport is
still poorly defined. PMA is a potent activator of conventional and
novel PKCs and PMA increases the rate of glucose uptake in many
different cell systems. In the present study, we show that PMA
treatment increases glucose uptake in 3T3-L1 adipocytes by two
mechanisms: a mitogen-activated protein kinase kinase-depen-
dent increase in GLUT1 (glucose transporter 1) expression levels
and a PKCλ-dependent translocation of GLUT1 towards the
plasma membrane. Intriguingly, PKCλ co-immunoprecipitated
with PKCβ II and did not with PKCβ I. Previously, we have des-
cribed that down-regulation of PKCβ II protein levels or inhibiting
PKCβ II by means of the myristoylated PKCβC2–4 peptide inhib-
itor induced GLUT1 translocation towards the plasma membrane
in 3T3-L1 adipocytes. Combined with the present findings, these
results suggest that the liberation of PKCλ from PKCβ II is an im-
portant factor in the regulation of GLUT1 distribution in 3T3-L1
adipocytes.
Key words: glucose uptake, myristoylated protein kinase Cβ
peptide inhibitor, phorbol ester, protein kinase C (PKC), 3T3-L1
adipocyte.
INTRODUCTION
In the recent years, the involvement of the PKC (protein kinase
C; EC 2.7.1.37) family in regulating glucose transport at different
levels has been identified. However, the underlying mechanisms
are poorly defined. Whereas some members of the PKC family are
essential for insulin-stimulated glucose transport, others may
function as negative-feedback inhibitors of insulin-stimulated
glucose transport and, finally, some members of the PKC family
can stimulate glucose transport independently of insulin [1–3].
The PKC family consists of at least 11 isoforms that can be
divided into three classes [4–6]. The conventional PKC isotypes
(α, β I, β II and γ ) and the novel PKC isoforms (δ, ε, η and θ ) are
activated by DAG (diacylglycerol). The atypical PKC isoforms
(ζ , λ and ι), which contain a relatively high constitutive activity,
can be activated by phosphatidic acid and phosphatidylinositides.
There is much evidence that PKCs play an important role in
regulating glucose transport in insulin-sensitive tissues. In particu-
larly, the atypical PKC isoforms have received much attention, as
PKCζ and/or PKCλ are essential during insulin-stimulated glu-
cose transport in both adipocytes and muscular cells (reviewed in
[1]). In 3T3-L1 adipocytes, transfection of kinase-inactive PKCλ
and PKCζ , which are highly homologous, severely decreased
glucose transport and prevented GLUT4 (glucose transporter 4)
translocation [7–9]. Since 3T3-L1 adipocytes contain solely
PKCλ [8], these observations suggest that in case of 3T3-L1
adipocytes, insulin acts through PKCλ to induce translocation of
GLUT4 from an intracellular vesicular storage pool to the PM
(plasma membrane).
PMA is a potent activator of the conventional and novel PKCs
and increases the rate of glucose uptake in 3T3-L1 adipocytes,
suggesting that the activation of DAG-sensitive PKC isoforms
stimulates the rate of glucose uptake [10–13]. However, activation
of PKCs results in the exposure of PKC sites sensitive to pro-
teolytic cleavage [14–16]. Consequently, chronic phorbol ester
treatment results in the proteolytic degradation, termed down-
regulation, of DAG-sensitive PKCs. This is in agreement with our
observation that in PMA-treated 3T3-L1 adipocytes, PKCβ II is
rapidly down-regulated [10]. In addition, inhibition of PKCβ II
by means of the myristoylated PKCβC2-4 peptide inhibitor
effectively increases glucose uptake, which strongly suggests that
part of the PMA-stimulated glucose uptake in 3T3-L1 adipocytes
is due to the loss of PKCβ II. In contrast with insulin that predo-
minantly stimulates the translocation of GLUT4 to the PM [17],
PMA stimulates glucose transport predominantly by increasing
the amount of GLUT1 at the PM [10,11].
The aim of this study was to provide more insight into the mech-
anism of PKC-regulated glucose uptake in 3T3-L1 adipocytes.
In the present study, we demonstrate that in 3T3-L1 adipo-
cytes activation of PKC by PMA increases GLUT1 expression
in an MAPKK (mitogen-activated protein kinase kinase)-depen-
dent manner. In addition, the translocation of GLUT1 from
intracellular pools to the PM is hampered upon inhibition of
PKCλ, and PKCβ II is associated with PKCλ. Since loss of PKCβ II
Abbreviations used: DAG, diacylglycerol; DMEM, Dulbecco’s modified Eagle’s medium; 2-DOG, 2-deoxyglucose; GLUT, glucose transporter; LDM,
low-density membrane; MAPKK, mitogen-activated protein kinase kinase; PKC, protein kinase C; PM, plasma membrane.
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stimulates glucose transport, the latter observation suggests that in
the case of 3T3-L1 adipocytes, liberation of PKCλ from PKCβ II is
an important phenomenon in the regulation of glucose transporter
redistribution.
MATERIALS AND METHODS
Materials
DMEM (Dulbecco’s modified Eagle’s medium) was purchased
from ICN Biomedicals (Aurora, OH, U.S.A.) and foetal calf
serum was purchased from PPA Laboratories (Linz, Austria). All
other culture reagents were purchased from Gibco BRL (Paisley,
Renfrewshire, Scotland, U.K.). The rabbit PKCλ antibody was
from Transduction Laboratories (Hamburg, Germany). The
mouse PKCβ I antibody and rabbit PKCβ II antibody were from
Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). The myris-
toylated PKCβ (amino acid sequence: FARKGALRQ) and myr-
istoylated PKCλ (amino acid sequence: JSIYRRGARRWRKL)
peptide inhibitors were purchased from the Department of Im-
munohematology and Blood Transfusion (Leiden University
Medical Center, Leiden, The Netherlands). BSA, 3-isobutyl-
1-methylxanthine, dexamethasone, 2-DOG (2-deoxyglucose),
PMA, U0126 and PD98059 were obtained from Sigma (St. Louis,
MO, U.S.A.). Rapamycin was obtained from Calbiochem
(Darmstadt, Germany). Recombinant human insulin was from
Eli Lilly and Co (Nieuwegein, The Netherlands). Dithiothreitol
was purchased from Research Organics (Santa Cruz, CA, U.S.A.)
and 1-[14C]-2-DOG (specific activity, 2.0 GBq/mmol) was pur-
chased from Amersham Biosciences (Little Chalfont, Bucks.,
U.K.). All other chemicals were of analytical grade.
Adipogenesis of 3T3-L1 adipocytes
The 3T3-L1 cells (A.T.C.C., Manassas, VA, U.S.A.) were fully
differentiated into adipocytes as described previously [10].
Glucose uptake assay
Fully differentiated 3T3-L1 adipocytes, subcultured in 12-well
plates, were incubated in DMEM without serum or in serum-free
DMEM with 10 µM U0126 and 20 µM PD98059 or 0.1 µM
rapamycin for 30 min. Subsequently, in the continuous presence
of the inhibitors, cells were treated either for 7 h with 0.1 µM
PMA in serum-free medium or for 90 min with 100 µM myris-
toylated PKCβ peptide inhibitor in reaction buffer containing
138 mM NaCl, 1.85 mM CaCl2, 1.3 mM MgSO4, 4.8 mM KCl,
0.2% (w/v) BSA and 50 mM Hepes adjusted to pH 7.4. Cells
were washed twice with PBS and the adipocytes were refreshed
with 760 µl of reaction buffer containing 333 kBq of 1-[14C]-2-
DOG and 40 µM 2-DOG. After 5 min of incubation at 37 ◦C,
2-DOG uptake was terminated by washing the cells three times
with ice-cold PBS containing 10 mM glucose. Subsequently, cells
were lysed in 1% (w/v) SDS and 0.2 M NaOH. The incorporated
radioactivity was measured by liquid-scintillation spectrometry.
Real-time reverse transcriptase–PCR analysis of GLUT1 and GLUT4
Fully differentiated 3T3-L1 adipocytes, subcultured in 12-well
plates, were incubated in DMEM without serum or in serum-free
DMEM with 10 µM U0126 and 20 µM PD98059 for 30 min. In
the continuous presence of the inhibitors, cells were subsequently
treated for 7 h with 0.1 µM PMA in serum-free medium. In ad-
dition, adipocytes were treated for 90 min with 100 µM my-
ristoylated PKCβ peptide inhibitor in a reaction buffer from the
glucose uptake assay (see above). After treatment, cells were
washed twice with PBS and total RNA was isolated using the
RNeasy mini kit (Qiagen, Hilden, Germany). RNA concen-
trations were determined from the spectrophotometric absorption
at 260 nm using the Genequant (Amersham, Eindhoven, The
Netherlands). Total RNA (1.0 µg) was denatured for 10 min at
70 ◦C and immediately cooled on ice. Reverse transcription was
performed using the Reverse Transcription System (Promega
Benelux, Leiden, The Netherlands) according to the manu-
facturer’s instructions. After annealing of random hexamers for
10 min at 20 ◦C, cDNA synthesis was performed for 60 min
at 42 ◦C followed by an enzyme inactivation step for 5 min at
95 ◦C. The GLUT1 forward primer was 5′-catccttattgcccaggtgttt-
3′ and the reversed primer was 5′-gaagacgacactgagcagcaga-3′; the
GLUT4 forward primer was 5′-cttctttgagattggccctgg-3′ and the re-
versed primer was 5′-aggtgaagatgaagaagccaagc-3′. All samples
were normalized for GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase) expression (forward primer 5′-ggccatccacagtcttct-
gg-3′ and the reversed primer 5′-accacagtccatgccatcactgcca-3′).
By means of SyBR Green Master Mix (PE Applied Biosystems,
Nieuwerkerk a/d IJssel, The Netherlands), amplifications were
performed by denaturation at 95 ◦C for 10 min, 40 cycles of 15 s
at 95 ◦C and 60 s at 60 ◦C on an ABI Prism 7700 Sequence
detection system (PE Applied Biosystems).
Western-blot analysis of GLUT1 and GLUT4 in different
cell fractions
Differentiated 3T3-L1 adipocytes, grown in T75 flasks, were tre-
ated for 5.5 h with or without 0.1 µM PMA in serum-free medium
and subsequently for 90 min in reaction buffer from the glucose
uptake assay (see above) with or without 20 µM myristoylated
PKCλ peptide inhibitor. After washing with PBS, adipocytes from
a T75 flask were scraped and the PM fraction and the LDM
(low-density membrane) fraction were obtained; the amounts
of GLUT1 and GLUT4 were determined by Western blotting
as described previously [10,18]. The bands were scanned using
the documentation and analysis system AlphaImagerTM 1220
(Biozym, Landgraaf, The Netherlands) and the integrated density
values were calculated with the computer program AlphaEase
v5.1 (Biozym).
Immunoprecipitation and detection of PKCβ II and PKCλ
Differentiated 3T3-L1 adipocytes, grown in 9 cm dishes, were
scraped in 750 µl of lysis buffer containing 1 mM Na3VO4,
150 mM NaCl, 5 mM NaF, 1 mM EGTA, 1 mM EDTA, 1%
(v/v) Nonidet P40, 0.5% (w/v) sodium deoxycholate, 1 tablet of
complete mini protease inhibitor cocktail per 50 ml and 50 mM
Tris adjusted to pH 7.4. Cell lysates were tumbled for 30 min at
4 ◦C and subsequently centrifuged at 13 000 g for 10 min at 4 ◦C.
The supernatant was precleared with a 10 µl slurry of ProtA beads
for 60 min at 4 ◦C after which the supernatant (approx. 1 mg) was
mixed with 5 µg of non-immunized rabbit serum or PKC-isotype-
specific antibodies for 90 min at 4 ◦C. Immunocomplexes were
collected by incubating with a 10 µl slurry of beads (ProtA for
rabbit polyclonal antibodies and ProtG for mouse monoclonal
antibodies) for 90 min at 4 ◦C. Beads were washed three times
with lysis buffer and once with a buffer containing 1 mM EDTA
and 50 mM Tris adjusted to pH 7.4. Subsequently, beads were
resuspended in sample buffer and subjected to SDS/PAGE after
which the proteins were transferred on to a PVDF membrane
(Immobilon P; Millipore, Bedford, MA, U.S.A.) by Western
blotting. Membranes were washed twice with PBS and blocked
for 2 h at room temperature in a buffer containing 0.25%
(v/v) Tween 20, 150 mM NaCl, 5% (w/v) milk powder and
50 mM Tris adjusted to pH 7.4 (TBS-M buffer). Subsequently,
membranes were incubated for 1 h at room temperature in TBS-M
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buffer containing the PKC-isotype-specific antibodies. The anti-
bodies were diluted 1:1000 for the detection of PKCβ I, PKCβ II or
PKCλ. Next, membranes were washed several times with TBS-M
buffer followed by an incubation for 1 h with goat anti-rabbit
(for detection of PKCβ II) or goat anti-mouse (for detection of
PKCβ I or PKCλ) antibodies conjugated to horseradish peroxidase
(1:10 000). Bands were visualized using ECL® (Amersham
Biosciences).
Data analysis
The results presented are means +− S.D. for 3–9 individual ex-
periments and statistical significance was determined by ANOVA.
For significance tests (P < 0.05), individual groups were com-
pared as described by Tukey–Kramer.
RESULTS
Characteristics of PMA- and myristoylated PKCβ peptide
inhibitor-stimulated glucose transport
The rate of glucose uptake was increased 3.7 +− 0.4-fold (n = 6)
after 7 h incubation of 3T3-L1 adipocytes with 0.1 µM PMA
(Figure 1A). Inhibition of MAPKK in these cells with either
U0126 or PD98059 significantly decreased PMA-stimulated
glucose transport compared with PMA-treated cells not exposed
to the inhibitors. However, in the presence of U0126 and
PD98059, PMA treatment still significantly increased the rate of
glucose uptake [2.0 +− 0.3-fold (n = 6) and 2.4 +− 0.8-fold (n = 6)
respectively]. Treatment of 3T3-L1 adipocytes with rapamycin,
which inhibits the mammalian target of rapamycin, did not
affect PMA-stimulated glucose transport. In contrast, inhibition
of PKCλ by incubation of the cells with the myristoylated PKCλ
peptide inhibitor (100 µM) during the final 90 min of PMA
treatment prevented stimulation of the rate of glucose transport
by PMA.
Incubation of 3T3-L1 adipocytes with 100 µM myristoylated
PKCβ peptide inhibitor for 90 min increased the rate of glucose
uptake 4.1 +− 1.5-fold (n = 9) (Figure 1B). Neither of the two
MAPKK inhibitors nor rapamycin affected the increase in the rate
of glucose uptake by the myristoylated PKCβ peptide inhibitor.
A co-incubation of the cells with the myristoylated PKCλ peptide
inhibitor and the myristoylated PKCβ peptide inhibitor at their
effective concentrations was not possible as it lysed the cells.
Effects of treatment with PMA or myristoylated PKCβ peptide
inhibitor on the expression of GLUTs
Treatment of the adipocytes with 0.1 µM PMA for 7 h increased
the amount of mRNA encoding GLUT1 approx. 6-fold when
compared with untreated cells (GLUT1/GAPDH: 0.015 +− 0.003
in control versus 0.087 +− 0.014 in PMA-treated cells; n = 3) (Fig-
ure 2A). Prolonged PMA treatment did not change the amount of
mRNA encoding GLUT4. Incubation of 3T3-L1 adipocytes for
90 min with 100 µM myristoylated PKCβ peptide inhibitor had
no significant effect on GLUT1 and GLUT4 mRNA levels.
Similarly as with the mRNA analyses, PMA treatment of adipo-
cytes increased the amount of GLUT1, but not GLUT4, at the
protein level, whereas incubation of cells with the myristoylated
PKCβ peptide inhibitor did not change either GLUT1 or GLUT4
protein levels (Figure 2B).
PMA increases the amount of GLUT1 through activation of MAPKK
To investigate whether prolonged PMA treatment increases
the expression of GLUT1 through signalling by activation of
Figure 1 Long-term PMA treatment and incubation with the myristoylated
PKCβ peptide inhibitor increases glucose uptake in 3T3-L1 adipocytes
The rate of glucose uptake was determined for cells treated with PMA (A) or with the myristoylated
PKCβ peptide inhibitor (B). For PMA, the rate of glucose uptake in unstimulated cells was
808 +− 137 fmol · min−1 · well−1 (n = 6). For the myristoylated PKCβ peptide inhibitor, the
rate of glucose uptake in unstimulated cells was 480 +− 267 fmol · min−1 · well−1 (n = 9).
Basal glucose uptake was set at 100 % to which all other values were related. The values
presented are means +− S.D. for 3–9 experiments; *significantly different from corresponding
untreated cells; #significantly different from 7 h of 0.1 µM PMA-treated cells. Incubation
with different inhibitors is shown at the bottom of each graph; control, no inhibitor present;
myr-lambda, myristoylated PKCλ peptide inhibitor.
MAPKK, 3T3-L1 adipocytes were pretreated with the MAPKK
inhibitors U0126 and PD98059 after which the cells were exposed
to 0.1 µM PMA for 7 h in the continuous presence of the inhi-
bitors. Figure 3 shows that the increase in PMA-mediated mRNA
(Figure 3A) and protein (Figure 3B) levels for GLUT1 were
completely prevented when the activity of MAPKK was blocked.
Although inhibition of PKCλ by incubating the PMA-treated
cells for 90 min with the myristoylated PCKλ peptide inhibitor
prevented stimulation of the rate of glucose transport (Figure 1A),
the increase in PMA-mediated GLUT1 mRNA and protein levels
was not lowered after 90 min incubation with the myristoylated
PKCλ peptide inhibitor (Figure 3).
Myristoylated PKCλ peptide inhibitor decreased the amount of
GLUT1 at the PM
Incubation of PMA-treated 3T3-L1 adipocytes with the myris-
toylated PKCλ peptide inhibitor lowered the increase in glucose
uptake (Figure 1) but not the increase in GLUT1 expression
(Figure 3). Therefore we investigated whether the peptide in-
hibitor affected the cellular redistribution of GLUT1. To this end,
c© 2004 Biochemical Society
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Figure 2 Long-term PMA treatment increases GLUT1 mRNA and protein
levels in 3T3-L1 adipocytes
Cells were treated for 7 h with 0.1 µM PMA or for 90 min with 100 µM myristoylated PKCβ
peptide inhibitor and the amounts of GLUT1 and GLUT4 were determined from mRNA (A)
and protein levels (B). For mRNA analyses, the values presented are means +− S.D. for three
experiments; *significantly different from untreated cells. For protein analyses, one representative
result from three separate experiments is presented. Arrows indicate bands representing the
glucose transporter. myr-PKCβ peptide, myristoylated PKCβ peptide inhibitor.
untreated and PMA-treated 3T3-L1 adipocytes were incubated
for 90 min with or without myristoylated PKCλ peptide inhibitor
(20 µM). By means of differential centrifugation the intracellular
vesicles (LDM) were separated from the PM and, subsequently,
the relative amounts of GLUT1 in these different fractions were
measured. The densitometric analyses are indicated below in
parentheses and indicate the relative changes (median; n = 3)
compared with the amount of GLUT1 in the fractions of un-
treated cells. Note that, during the glucose uptake, cells could
be treated with 100 µM myristoylated PKCλ peptide inhibitor,
whereas this had to be lowered to 20 µM when the adipocytes were
subjected to differential centrifugation to maintain the integrity of
the LDM and PM fractions (results not shown). Figure 4 shows
that the addition of myristoylated PKCλ peptide inhibitor for
90 min increased the amount of GLUT1 in the LDM fraction
(1.17-fold) and decreased the amount of GLUT1 in the PM
fraction (0.79-fold). Similar to our earlier report [10], the amount
of GLUT1 increased in both the LDM (1.26-fold) and PM (1.21-
fold) fractions of cells treated for 7 h with 0.1 µM PMA. When
PMA-treated cells were incubated with the myristoylated PKCλ
peptide inhibitor during the last 90 min of PMA treatment, the
amount of GLUT1 in the PM fraction decreased (1.08-fold) and
the amount of GLUT1 in the LDM fraction increased (1.64-fold)
compared with the respective amounts in PMA-treated 3T3-L1
adipocytes not exposed to the peptide inhibitor.
Co-immunoprecipitation of PKCβ II and PKCλ
Previously, we reported that depletion or inhibition of PKCβ II
promotes the translocation of GLUT1 to the PM [10]. Since
this translocation of GLUT1 to the PM requires PKCλ activity
(Figure 4), we investigated whether there is an interaction between
PKCβ II and PKCλ. Figure 5 shows that beads coupled with
Figure 3 Inhibition ofMAPKK prevents PMA-stimulated increases in GLUT1
mRNA and protein levels in 3T3-L1 adipocytes
Untreated and PMA-treated cells were harvested and the amount of GLUT1 was investigated
from mRNA levels (A) and protein levels (B). For mRNA analyses, the values presented are
the means +− S.D. for four experiments; *significantly different from untreated cells. For protein
analyses, one representative result of two separate experiments is shown. The arrow indicates a
band representing the glucose transporter. Treatment with inhibitors is indicated below the graph;
control, not exposed to inhibitor; myr-PKCλ peptide, myristoylated PKCλ peptide inhibitor.
Figure 4 Translocation of GLUT1 from intracellular vesicles to the PM
in PMA-treated 3T3-L1 adipocytes is prevented by the myristoylated PKCλ
peptide inhibitor
Cells were subjected to differential centrifugation to yield LDM and PM fractions. Proteins
(20 µg) of these fractions were separated by means of SDS/PAGE and subjected to Western
blotting. One representative result of three separate experiments is presented. Arrows indicate
bands representing GLUT1. Myr-PKCλ peptide, myristoylated PKCλ peptide inhibitor. The
treatment condition (–, without, +, with) is indicated below the graph.
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Figure 5 Immunoprecipitation of PKCβ II co-immunoprecipitates PKCλ in
3T3-L1 adipocytes
A lysate of 3T3-L1 adipocytes treated with or without 100 µM myristoylated PKCβ peptide
inhibitor was incubated with beads coupled with either non-immunized rabbit antiserum (n.i.),
anti-PKCλ, anti-PKCβ I or anti-PKCβ II . Subsequently, the beads were precipitated and subjected
to SDS/PAGE followed by Western blotting. Membranes were probed with anti-PKCβ I (top
panels), anti-PKCβ II (middle panels) or anti-PKCλ (lower panels). One representative result
from three separate experiments is shown, except for the right most lane, which was performed
twice. Arrows indicate bands representing the PKC isoforms. IP, immunoprecipitation; IB,
immunoblotting.
non-immunized rabbit antiserum did not precipitate PKCβ I,
PKCβ II or PKCλ from a lysate of 3T3-L1 adipocytes. Immuno-
precipitation of beads coupled with anti-PKCλ antibody im-
munoprecipitated only PKCλ and not PKCβ I or PKCβ II. Immuno-
precipitation of beads coupled with anti-PKCβ I antibody
immunoprecipitated only PKCβ I and not PKCβ II or PKCλ. When
a lysate of 3T3-L1 adipocytes was incubated with beads coupled
with anti-PKCβ II antibody, it did not immunoprecipitate PKCβ I
but did PKCβ II, and co-immunoprecipitated PKCλ. When 3T3-
L1 adipocytes were treated for 90 min with 100 µM myristoylated
PKCβ peptide inhibitor before immunoprecipitation of PKCβ II,
the amount of PKCλ that was co-immunoprecipitated was de-
creased when compared with the amount of PKCλ that was co-
immunoprecipitated with PKCβ II in a lysate of untreated 3T3-L1
adipocytes.
DISCUSSION
The present study examined how different PKC isoforms are
involved in promoting glucose uptake in 3T3-L1 adipocytes. We
observed that an increase in PMA-stimulated glucose transport
was partially attenuated on inhibition of MAPKK. In addition,
the increase in PMA-stimulated glucose transport was associated
with an increase in GLUT1 mRNA and protein levels. This PMA-
induced increase in GLUT1 expression was prevented by inhibi-
tion of MAPKK. Furthermore, incubation with the myristoylated
PKCλ peptide inhibitor completely attenuated PMA-stimulated
glucose transport but did not affect PMA-stimulated increase
in GLUT1 levels. However, incubation of PMA-treated 3T3-L1
adipocytes with the PKCλ peptide inhibitor decreased the amount
of GLUT1 at the PM and increased the amount of GLUT1 at
the intracellular vesicles. Finally, in 3T3-L1 adipocytes, immun-
oprecipitation of PKCβ II co-immunoprecipitated PKCλ. These
results demonstrate that PMA treatment increases glucose uptake
in 3T3-L1 adipocytes by two mechanisms, namely increase in
GLUT1 expression levels and translocation of GLUT1 towards the
PM. Moreover, given our previous findings on how inactivation of
PKCβ II stimulates GLUT1-mediated glucose transport [10], the
present results suggest that PKCβ II and PKCλ are associated and
that dissociation of PKCλ is an important mechanism to initiate
GLUT1 translocation from intracellular vesicles to the PM.
Several studies have demonstrated that PMA, known to stimu-
late PKC, increases the rate of glucose transport in 3T3-L1 adi-
pocytes [11–13,19]. In the present study, treatment of 3T3-L1
adipocytes for 7 h with 0.1 µM PMA increased the rate of glucose
uptake by approx. 4-fold. When cells were treated with PMA in
the presence of the MAPKK inhibitors U0126 and PD98059, the
rate of glucose uptake was still significantly increased but its
magnitude was nearly halved when compared with PMA-treated
cells not incubated with the inhibitors. Inhibition of the mam-
malian target of rapamycin, a serine/threonine kinase homologous
with phosphatidylinositol 3′-kinase, by rapamycin did not de-
crease the rate of glucose uptake in PMA-treated adipocytes,
whereas in 18 h insulin-treated L6 muscle cells, glucose trans-
port was increased due to increased GLUT1 expression in a
rapamycin-sensitive manner [20,21]. These results show that
part of the stimulatory effect of PMA on glucose uptake in
3T3-L1 adipocytes is mediated by MAPKK, a component of
the Ras-MAPK pathway [22]. Since this pathway is typically
activated by growth factors and mitogens to alter transcription
factor activity, we measured the expression levels of GLUT1
and GLUT4. No differences were found in the level of GLUT4,
whereas the amount of GLUT1 both at the mRNA and the
protein level markedly increased in PMA-treated adipocytes
when compared with untreated cells. The increases in GLUT1
expression levels were prevented when MAPKK was inhibited
either by U0126 or PD98059. Taken together, these results
show that PMA stimulates the Ras-MAPK pathway to promote
GLUT1 expression. Our results are in agreement with previous
reports, which demonstrate that introducing active mutants of
Ras, SHP2, Raf-1 or MAPKK into 3T3-L1 adipocytes, which
increase the activity of the Ras-MAPK pathway, increases the
expression of GLUT1 but not of GLUT4 [23–26]. In Cos-7
cells, PMA-sensitive PKC isoforms activate the Ras-MAPK
pathway at the level of Raf [27]. It should be mentioned that
PMA is capable of stimulating the Ras-MAPK pathway without
the requirement of PKC (reviewed in [28,29]). As in 3T3-L1
adipocytes, PMA-induced activation of MAPK is inhibited by the
PKC inhibitors Go¨-6976, bisindolylmaleimide I and chelerythrine
chloride [30]; it is most probable that PMA stimulates the
expression of GLUT1 in our cells through the stimulation of con-
ventional and novel PKCs, which in turn increase the activity of
Raf.
Treatment of 3T3-L1 adipocytes by PMA very effectively
increases the rate of glucose uptake. However, inhibition of
PKC, most probably PKCβ II, by incubating 3T3-L1 adipocytes
with the myristoylated PKCβ peptide inhibitor also stimulates
an increase in glucose uptake, as it promotes the translocation
of GLUT1 from intracellular compartments to the PM [10].
Stimulation of glucose uptake in adipocytes by the PKCβ peptide
inhibitor is not attenuated by inhibition of MAPKK, indicating
that the translocation of GLUT1 to the PM is not dependent
on the Ras-MAPK pathway. Similarly, a significant part of the
PMA-simulated increase in glucose uptake is also not sensitive
to MAPKK inhibition. Persistent activation of PKC by PMA
causes down-regulation of PMA-sensitive PKCs [14–16] and,
c© 2004 Biochemical Society
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accordingly, PKCβ II is completely down-regulated after 7 h of
0.1 µM PMA treatment, whereas the other PMA-sensitive PKCs
(PKCβ I, PKCγ , PKCδ and PKCθ ) are still present [10]. Taken
together, this is a strong indication that the MAPKK-insensitive
part of PMA-stimulated glucose transport is due to loss of PKCβ II.
The increased rate of glucose uptake in PMA-treated 3T3-L1
adipocytes was completely prevented when cells were incubated
with the myristoylated PKCλ peptide inhibitor. This is not
explained by a decreased GLUT1 expression as PMA-mediated
increase in GLUT1 levels was not lowered when PMA-treated
cells were exposed to 90 min incubation with the myristoy-
lated PKCλ peptide inhibitor. Therefore we analysed GLUT1 ex-
pression in the LDM fraction (representing the intracellular
vesicles) and the PM fraction in cells that were exposed to
the PKCλ peptide inhibitor. The amount of GLUT1 decreased
at the PM and tended to increase in the intracellular vesicles
when control cells were treated with the PKCλ peptide inhibitor.
As reported previously, PMA treatment of 3T3-L1 adipocytes
increases GLUT1 levels in both the LDM and the PM fraction
[10]. However, in the presence of the PKCλ peptide inhibitor,
GLUT1 levels in the PM fraction were no longer increased
compared with the levels in untreated adipocytes. In addition, it
appears that the GLUT1 proteins are arrested in the intracellular
vesicles as the highest amount of GLUT1 was measured in
the LDM fraction of PMA-treated adipocytes in which PKCλ
was inhibited. Taken together, these results demonstrate the
importance of PKCλ in the translocation of GLUT1 from intra-
cellular vesicles to the PM. There are numerous reports demon-
strating the importance of atypical PKCs in insulin-stimulated
translocation of GLUT4 from intracellular vesicles to the PM
(reviewed in [1]). Our results show that PKCλ is also involved
in the translocation of GLUT1, which strengthens the idea that
atypical PKCs are critical for activating glucose transport
responses.
Given the pivotal role of PKCλ in GLUT1-mediated glucose
transport, which is stimulated on loss of function of PKCβ II [10],
we wondered whether the two PKC isoforms are closely asso-
ciated. Indeed, immunoprecipitation of PKCβ II from a lysate of
3T3-L1 adipocytes co-immunoprecipitated PKCλ. Note, however
that immunoprecipitation of PKCλ did not co-immunoprecipitate
PKCβ II. The reason for this could be differences in stoichiometry,
i.e. there is relatively more PKCλ not associated with PKCβ II
than there is PKCβ II not associated with PKCλ. In contrast with
immunoprecipitation of PKCβ II, immunoprecipitation of PKCβ I
did not co-immunoprecipitate PKCλ. These results demonstrate,
for the first time, that PKCλ is associated with PKCβ and, more
specifically, that PKCλ is associated with PKCβ II and not with
PKCβ I. Since the GLUT1-mediated rate of glucose uptake is
increased on inhibition of PKCβ II, these results suggest that the
liberation of PKCλ from PKCβ II initiates the translocation of
GLUT1 to the PM. The two PKCβ isoforms are identical except
for their C-terminal V5 region [31]. Interestingly, when we treated
the adipocytes with the PKCβ peptide inhibitor, which acts as
a pseudosubstrate, less PKCλ was precipitated, indicating that
the inhibitor competes with PKCλ for binding to PKCβ II at the
substrate binding domain. Although PKCβ I and PKCβ II share
an identical substrate-binding domain, PKCβ I does not associate
with PKCλ.
In human U937 monocytic cells, MOLT-4 T-lyphoblastoid cells
and in NIH-3T3 fibroblasts, PKCβ I and PKCβ II are differently
localized [32–34], and PKCβ II, and not PKCβ I, co-localizes
with actin microfilaments and the cytoskeleton. Moreover, the
ability of PKCβ II to associate with the cytoskeleton was inhibited
on disruption of the actin-depolymerizing agent, cytochalasin
D. Interestingly, insulin-stimulated GLUT4 translocation is also
inhibited by cytochalasin D [35], as insulin induces cortical actin
remodelling and this dynamic actin rearrangement is imperative
for insulin-stimulated glucose transport [36]. During this cortical
actin remodelling, PKCλ is recruited to these actin structures [37].
On the basis of our findings that PKCβ II associates with PKCλ
and that in different models PKCβ II localizes with actin struc-
tures, it is tempting to speculate that at the cortical actin structures
PKCβ II binds and, hence, inhibits PKCλ, and that dissociation
of PKCλ from PKCβ II is important to promote translocation of
glucose transporters to the PM. In addition, in several cell models,
including 3T3-L1 adipocytes, insulin promotes the alternative
splicing of PKCβ into PKCβ II, rather than PKCβ I, which further
strengthens the suggestions of an involvement of PKCβ II in
regulating glucose uptake [38–40]. It remains to be determined
whether the dissociation of PKCλ from PKCβ II also plays a role
in (insulin-stimulated) GLUT4 translocation to the PM.
In summary, our results demonstrate that PMA stimulates
GLUT1 expression in a Ras-MAPK-dependent manner and
translocation of GLUT1 from intracellular vesicles to the PM
requires PKCλ. In 3T3-L1 adipocytes, PKCλ is associated with
PKCβ II. Given that inhibition of PKCβ II stimulates GLUT1-
mediated glucose transport, these results suggest that release of
PKCλ from PKCβ II is an important mechanism in the regulation
of glucose transporter distribution.
We thank Professor (Dr) A. Schu¨rmann (Department of Pharmacology, German Institute of
Human Nutrition, Potsdam-Rehbru¨cke, Germany) for providing us the GLUT1 and GLUT4
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